Company Shares of Threshold Pharmaceuticals (NASDAQ:THLD) Drops by -12.64%

Threshold Pharmaceuticals (NASDAQ:THLD) has risen sharply, recording gains of 30% in the past 4 weeks. However, the stock has corrected -12.64% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 27.93% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The company shares have dropped -85.85% from its 1 Year high price. On Sep 18, 2015, the shares registered one year high at $5.28 and the one year low was seen on Feb 24, 2016. The 50-Day Moving Average price is $0.48 and the 200 Day Moving Average price is recorded at $0.41.

The stock has recorded a 20-day Moving Average of 24.16% and the 50-Day Moving Average is 36.86%.


Threshold Pharmaceuticals (NASDAQ:THLD): On Fridays trading session , Opening price of the stock was $0.639 with an intraday high of $0.66. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.6012. However, the stock managed to close at $0.6115, a loss of 2.98% for the day. On the previous day, the stock had closed at $0.6303. The total traded volume of the day was 680,494 shares.

In an insider trading activity, Fernandes Joel A, officer (Senior Vice President) of Threshold Pharmaceuticals Inc, executed a transaction worth $14,106 on September 28, 2015. A total of 3,562 shares were purchased at an average price of $3.96. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Thresholds investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Thresholds [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.